The effect of 4% icodextrin solution on adhesiolysis surgery time at the Hartmann’s reversal: a pilot, multicentre, randomized control trial vs lactated Ringer’s solution

Abstract

Icodextrin treatment resulted in a decreasing trend in adhesiolysis time. The use of 4% ID solution in peritonitis patients seemed to be safe. Because of larger than expected variations in adhesiolysis times, this pilot study was underpowered to meet the study end-point and further statistical modelling estimated that significance cannot be reached within a reasonable time scale. Other models should be used to evaluate the efficacy of anti-adhesive agents.

Adhesion-related readmissions after surgery for deep endometriosis with the use of icodextrin—long-term results

“…The safety and efficacy of icodextrin in reducing adhesion formation has been shown in many animal studies [4][5][6][7]. However, few human studies focusing on the efficacy of icodextrin on adhesion prevention have been published to date [9][10][11][12]16]. There have been even fewer studies evaluating the clinical benefits of icodextrin after general surgery, the results of which seem to be somewhat conflicting [17,18].…”

Two icodextrin exchanges per day in peritoneal dialysis patients with ultrafiltration failure: one center’s experience and review of the literature

“…In a study in humans, Kössi et al [24] found that icodextrin treatment reduced adhesion formation-post surgery. Adhesions are a common complication of serious peritonitis especially those caused by pseudomonas and enteric organisms.…”

P.O.P.A. Study: Prevention of Postoperative Abdominal Adhesions by Icodextrin 4% Solution After Laparotomy for Adhesive Small Bowel Obstruction. A Prospective Randomized Controlled Trial

“…Kossi demonstrated that icodextrin was able to reduce the number of adhesions and adhesiolysis time during Hartmann reversal but without reaching statistical significance. 23 Further data were obtained by Ariel Registry which enrolled 7,000 patients operated with open and laparoscopic surgery for oncological and non-oncological diseases. These large numbers confirmed the safety of this fluid with regard to bowel leaks and wound dehiscence.…”